Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.
InMed Pharmaceuticals ( (INM) ) has provided an update.
InMed Pharmaceuticals announced positive results from a long-term preclinical study of its drug candidate INM-901 for Alzheimer’s Disease. The study showed that INM-901 significantly reduced neuroinflammation markers and neurodegeneration biomarkers, presenting a promising new approach to treating Alzheimer’s by targeting neuroinflammation, an emerging drug target beyond traditional treatments.
More about InMed Pharmaceuticals
InMed Pharmaceuticals Inc. is a pharmaceutical company dedicated to developing a pipeline of proprietary small molecule drug candidates aimed at addressing diseases with high unmet medical needs.
YTD Price Performance: 3.12%
Average Trading Volume: 39,069
Technical Sentiment Consensus Rating: Buy
Current Market Cap: $3.58M
Learn more about INM stock on TipRanks’ Stock Analysis page.
